Management of Malignant Pleural Effusion With Indwelling Pleural Catheter Versus Silver Nitrate Pleurodesis

• Status: Unknown status
• Trial end date: 2020-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary goal of this study is to compare well-defined pleural effusion management success outcomes in patients with malignant or paramalignant pleural effusions who were treated with Indwelling pleural catheter insertion compared with those treated with siver nitrate pleurodesis. It is also to demonstrate the effectiveness of silver nitrate pleurodesis. It is also important to evaluate frequent adverse events of silver nitrate pleurodesis in patients with malignant pleural effusion

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Lidocaine; Silver Nitrate

Criteria

Inclusion Criteria:

1. Unilateral symptomatic recurrent malignant pleural effusion patients who fulfill the criteria for pleurodesis (i.e. positive pleural biopsy or cytology for malignancy, a Karnofsky index score of more than 60 and life expectancy of more than one year).

2. Rapidly accumulated undiagnosed pleural effusion .

3. Age : 30-75 years old.

Exclusion Criteria:

1. Transudative pleural effusion.

2. Exudative pleural effusion due to causes other than malignancy ( i.e. parapnuemonic , post-tuberculous pleural effusion )

3. Presence of hemorrhagic diathesis ( prothrombin time <50% and platelet count <80,000/mm 3 )

4. Active pleural or systemic infection.

5. Neoplastic infiltration of the skin at the site of pleural catheter insertion.

6. Malignant pleural effusion with trapped lung or loculated pleural effusion.

7. Previous lobectomy or pneumonectomy on the affected side.

8. Karnofsky index score> 50.